

Changes in morbimortality patterns due to heart failure in patients of the Unified Health System and their economic impacts: a challenge for Public Health management

Authors:

Matheus Manoel Diogo Lins¹, Vivian Fernandes Alves Borges²

Affiliations:

¹Medical Student, Universidade do Grande Rio, Rio de Janeiro, Rio de Janeiro, Brazil

²Medical Student, Universidade Estacio de Sá, Rio de Janeiro, Rio de Janeiro, Brazil

Abstract:

A descriptive ecological study was conducted to form a profile of morbimortality due to cardiac care in the Brazilian population based on patients registered in the Department of Informatics of the Unified Health System (DATASUS). The results of the article show that, during the studied period, 2,984,424 patients were hospitalized due to cardiac care, predominantly represented by males, with the age group predominating in elderly individuals between 70 and 79 years old, of white ethnicity, and with a character of emergency care. The average hospitalization cost was estimated at R\$ 1,371.67, generating an annual cost to the Brazilian economy of R\$ 341,137,000.

Summary:

Background: Heart failure (HF) is a complex syndrome considered the common endpoint of various cardiovascular diseases, and due to its high prevalence, it is necessary to understand its morbidity and mortality profile.

Objective: To describe the morbidity and mortality profile of HF among patients registered in the Department of Informatics of the Unified Health System (DATASUS) and its impact on public health between 2008 and 2020.

Materials and Methods: A descriptive epidemiological study was conducted using data obtained from the TABNET application developed by DATASUS. Patients of both sexes, without age restrictions, who were hospitalized with a confirmed diagnosis of HF in Brazil, from January 2008 to December 2020 were included. Data were stratified by sex, age group, self-reported ethnicity/race, type of healthcare plan, and nature of care.

Results: During the study period, 2,984,424 patients were hospitalized due to HF in the SUS. The majority were male: 1,533,469 (51.38%); elderly with the predominant age group between 70 and 79 years: 788,367 (26.41%); of white ethnicity: 1,102,860 (36.95%); private healthcare plan: 1,196,559 (46.10%), and with emergency care character: 2,827,354 (94.73%). The average hospitalization cost was estimated at R\$ 1,371.67, generating an annual cost to the Brazilian economy of R\$ 341,137,000.

Conclusions: Heart failure is an important public health problem, causing not only high morbidity in affected individuals but also a significant financial burden on the Unified Health System (SUS).

INTRODUCTION:

Heart failure (HF) is a complex cardiovascular syndrome characterized by the heart's inability to provide the basic adequate amount of blood to meet metabolic demands, or doing so at the cost of high filling pressures. It is often the end result of various cardiovascular diseases and has a poor prognosis, with mortality rates reaching 50% in the 5 years following diagnosis. It has a

multifactorial etiology, with chronic ischemic heart disease associated with systemic arterial hypertension being prominent. However, in regions with low socioeconomic status, it may be related to Chagas disease, endomyocardial fibrosis, and rheumatic valvulopathy. The typical signs and symptoms of HF result from reduced cardiac output and/or high pressures exerted on the cardiac chambers during the filling phase.

HF can be classified based on the following criteria: severity of symptoms (New York Heart Association functional classification - NYHA), ejection fraction (HFpEF, HFmrEF, and HFrEF), and disease progression (various stages). Therapeutic advances observed in the treatment of arterial hypertension, acute myocardial infarction, and HF have allowed for greater survival and improved quality of life for these patients. However, there has been an increase in the incidence of HF, estimated at 1 to 2% of the world's population, as well as an increase in hospital costs, placing a burden on healthcare systems in various countries, especially those with a growing elderly population. By 2025, the population over 60 years old in Brazil will be the sixth largest in the world, which will reflect in an increase in HF cases and costs for its treatment for the Unified Health System (SUS). However, it is still necessary to deepen these analyses because there is a lack of epidemiological data, which is important for proper planning of preventive methods.

Therefore, recognizing HF as one of the main cardiovascular diseases and its high mortality and costs to public health, it is important to recognize the morbidity profile of HF in Brazil, considering the power of epidemiology in helping to plan effective public policies for the prevention and control of the disease. In order to support this recognition, this article aims to describe the profile of morbidity and mortality due to HF among patients registered in the Department of Health Informatics of the Unified Health System (DATASUS) and its impact on public health between 2008 and 2020.

MATERIALS AND METHODS

A descriptive ecological epidemiological study was conducted, and the data were obtained through the Department of Health Informatics of the Brazilian Unified Health System (DATASUS), using the Hospital Information System (SIH) platform, accessed in March 2021. patients of both sexes, without age restriction, who were admitted with a confirmed diagnosis of heart failure classified in the category I59.0, Chapter IX- Diseases of the Circulatory System, in the version corresponding to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), during the period from January 2008 to December 2020, were included. The following variables were analyzed: the number of annual hospitalizations for heart failure, the percentage frequency of elective and emergency admissions, the number of hospitalizations by sex, age group, declared race/color, and type of healthcare (private and public). Statistical analysis The collected data were transcribed and organized into a Microsoft Office Excel (Microsoft®, 2010) spreadsheet for statistical analysis, applying the simple descriptive statistical method, using absolute and relative frequencies for qualitative evaluation. To calculate the mortality rate, the ratio between deaths and hospitalizations for the same disease during the study period was calculated and then multiplied by 100, obtaining the value in percentage.

Ethical considerations

According to CNS Resolution 510/2016, submission to the Research Ethics Committee was not required due to the nature of the study (ecological).

RESULTS

Table 1 shows the data on hospitalizations, deaths, and mortality due to heart failure in patients registered in the Department of Health Informatics of the Brazilian Unified Health System (DATASUS) by region and year of service.

During the studied period, there were 2,984,424 hospitalizations and 296,166 deaths, corresponding to a mortality rate of 9.92%.

The southeastern region of the country showed a higher percentage of hospitalizations (41.70%), deaths (47.90%), and mortality rate (11.38%).

The total number of hospitalizations for heart failure among patients registered in DATASUS decreased by approximately 62.82% between 2008 and 2020. Meanwhile, the mortality rate increased by about 38.97% in the same period for the same patients.

(Table 1). Table 1: Admissions, deaths, and mortality due to heart failure in patients registered in the Hospital Information System of the Brazilian Unified Health System stratified by region and year of service. Brazil, 2008-2020.

Variables/ year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total	Total
	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	%
Admissions by region															
North	15.124	14.336	13.768	13.617	13.106	12.730	11.896	11.216	10.625	10.681	11.108	11.136	8.621	157.964	5,20%
North East	62.806	64.832	63.647	63.007	59.548	57.169	54.178	51.327	48.805	48.151	45.740	45.120	34.908	699.238	23,40%
Southeast	112.246	114.138	110.058	111.206	103.382	98.295	93.855	91.377	89.267	86.297	81.991	82.147	72.660	1.246.919	41,70%
South	57.720	58.137	57.138	54.957	50.787	50.348	47.988	48.605	49.810	48.098	47.427	47.965	41.341	660.321	22,10%
Midwest	21.091	20.493	20.191	18.915	17.590	17.901	16.460	16.378	15.953	15.497	14.567	13.476	11.470	219.982	7,30%
Total	268.987	271.936	264.802	261.702	244.413	236.443	224.377	218.903	214.460	208.724	200.833	199.844	169.000	2.984.424	100%
	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	Abs.	%
deaths by region															
North	1.021	1.014	1.145	1201	1.192	1.117	1.061	1.124	1.320	1.205	1.250	1.430	1.126	15.206	5,13%
North East	4.469	4.776	4.767	5.235	5.208	5.083	5.024	5.171	5.342	5.044	5.009	5.028	4.288	64.444	21,70%
Southeast	10.979	11.579	11.856	12.086	11.200	10.796	10.307	10.609	10.951	10.783	10.332	10.561	9.905	141.944	47,90%
South	4.050	4.200	4.344	4.331	4.002	4.370	4.103	4.172	4.367	4.138	4.345	4.336	4.009	54.767	18,40%
Midwest	1.561	1.600	1.640	1.533	1.517	1.582	1.557	1.697	1.635	1.486	1.401	1.451	1.145	19.805	6,60%
Total	22.080	23.169	23.752	24.386	23.119	22.948	22.052	22.773	23.615	22.656	22.337	22.806	20.473	296.166	100%
Mortality rate															
North	8,21	8,52	8,97	9,32	9,46	9,71	9,83	10,40	11,01	10,85	11,12	11,12	11,41	9,92	*
North East	6,75	7,07	8,32	8,82	9,10	8,77	8,92	10,02	12,42	11,28	11,25	12,84	13,06	9,63	*
Southeast	9,78	10,14	10,77	10,87	10,83	10,98	10,98	11,61	12,27	12,50	12,60	12,86	13,63	11,38	*
South	7,02	7,22	7,60	7,88	7,88	8,68	8,55	8,58	8,77	8,60	9,16	9,04	9,70	8,29	*
Midwest	7,40	7,81	8,12	8,10	8,62	8,84	9,46	10,36	10,25	9,59	9,62	10,77	9,98	9,00	*

Total	8,21	8,52	8,97	9,32	9,46	9,71	9,83	10,40	11,01	10,85	11,12	11,41	12,11	9,92	*
-------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	------	---

Regarding age groups, the population aged between 70 and 79 years old accounted for the highest percentage of hospitalizations (26.41%). As for deaths and mortality rates, the age group ≥ 80 years old was predominant, with 32.41% and 14.99%, respectively, according to Table 2.

Table 2: Admissions, deaths, and mortality due to heart failure in patients registered in the Brazilian Unified Health System Hospital Information System stratified by age group. Brazil, 2008 to 2020 (absolute and relative frequencies).

Age group	Admissions		Deaths		Mortality rate
	Abs.	%	Abs.	%	
<1 ano	17.565	0,58	1.902	0,64	10,83
1 a 4 anos	9.997	0,33	468	0,15	4,68
5 a 9 anos	5.921	0,19	245	0,08	4,14
10 a 14 anos	6.966	0,23	423	0,14	6,07
15 a 19 anos	10.473	0,35	804	0,27	7,68
20 a 29 anos	35.616	1,19	2.687	0,90	7,54
30 a 39 anos	85.022	2,84	5.872	1,98	6,91
40 a 49 anos	212.978	7,13	13.887	4,68	6,52
50 a 59 anos	468.622	15,70	33.013	11,14	7,04
60 a 69 anos	702.398	23,53	59.164	19,97	8,42
70 a 79 anos	788.367	26,41	81.692	27,58	10,36
≥ 80 anos	640.499	21,46	96.009	32,41	14,99
Total	2.984.424	100	296.166	100	9,92

In relation to gender, Table 3 shows that the majority of hospitalizations occur in the male population. However, the number of deaths and the mortality rate were higher in the female gender.

Table 3: Admissions, deaths and mortality due to heart failure in patients registered in the Hospital Information System of the Brazilian Unified Health System stratified by gender. Brazil, 2008-2020.

Gener	Admissions		Deaths		Mortality rate
	Abs.	%	Abs.	%	
Male	1.533.469	51,38	147.612	49,84	9,63
Female	1.450.955	48,61	148.554	50,19	10,40
Total	2.984.424	100	296.166	100	9,92

In relation to race/ethnicity by year, Table 4 shows that white individuals had the highest rates of hospitalizations and deaths during the analyzed period. However, in terms of mortality rate, the "unspecified" group had the highest numbers, followed by the yellow race. Indigenous people had the lowest mortality rate.

Table 4: Admissions, deaths, and mortality due to heart failure in patients registered in the Brazilian Unified Health System (SUS) stratified by race/ethnicity. Brazil, 2008-2020.

Race/ethnicity	Admissions	Deaths	Mortality rate
----------------	------------	--------	----------------

	Abs.	%	Abs.	%	
White	1.102.860	36,95	109.900	37,10	9,97
Black	137.410	4,60	12.963	4,37	9,43
Yellow race	856.198	28,68	77.770	26,25	9,08
Amarela	28.255	0,94	2.881	0,97	10,20
indigenous	3.543	0,11	279	0,09	7,87
no information	856.158	28,68	92.373	31,18	10,79
Total	2.984.424	100	296.166	100	9,92

The table 5 shows that the public healthcare system presented the highest mortality rate (11.33%). Regarding the number of hospitalizations, the majority occurred in the private healthcare system (40.09%). The group with no information on the type of hospitalization, described as "Unknown" had the highest number of deaths (38.99%).

Table 5: Admissions, deaths, and mortality rates due to heart failure in patients registered in the Brazilian Public Healthcare System stratified by healthcare system type. Brazil, 2008-2020.

Regime	Admissions		Deaths		Mortality rate
	Abs	%	Abs	%	Abs
Public	759.818	25,45	86.111	29,07	11,33
Private	1.196.559	40,09	94.565	31,92	7,90
Unknown	1.028.047	34,44	115.490	38,99	11,23
Total	2.984.429	100	296.166	100	9,92

Table 6 shows that cases attended to emergencies had the highest mortality rate (10.02%), as well as the highest number of hospitalizations (94.74%) and deaths (95.65%).

Table 6: Hospitalizations, deaths, and mortality rates for heart failure patients registered in the Hospital Information System of the Brazilian Unified Health System, stratified by type of care. Brazil, 2008-2020.

Category	Admissions		Deaths		Mortality rate
	Abs	%	Abs	%	Abs
Elective	156.520	5,24	12.815	4,32	8,19
Urgency	2.827.354	94,74	283.297	95,65	10,02
Others	550	0,01	54	0,01	9,81
Total	2.984.424	100	296.166	100	9,92

Table 7 shows an increase in the time ($\uparrow 5.38\%$) and average value of hospitalization ($\uparrow 105\%$) between 2008 and 2020. The mortality rate also increased during this period ($\uparrow 47.50\%$).

Table 7: Average value per admission and average length of stay for heart failure patients registered in the Hospital Information System of the Brazilian Unified Health System (SUS), 2008-2020.

V/Y*	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Média
VMI* *	920,78	1.091,15	1.151,42	1.180,58	1.228,61	1.297,34	1.406,26	1.498,24	1.558,96	1.630,77	1.686,93	1.756,20	1.895,66	1.371,67
ALS* **	6,4	6,4	6,5	6,6	6,7	6,9	7,1	7,3	7,4	7,5	7,7	7,7	7,5	7
MR** **	6	6,1	6,0	6,0	6,4	6,6	6,6	7,1	7,2	7,4	7,5	7,7	7,8	6,7

*V/Y= Variables x Year

**AVH= Average value per hospitalization in reais

***ALS= Average length of stay in days

****MR= Mortality rate

DISCUSSION

Morbidity refers to the number of individuals in a population affected by a particular disease or health problem. The morbidity patterns of a population can be measured through hospital admissions, which are thus called hospital morbidity⁸.

Morbidity is a widely used parameter for epidemiological surveillance, organization, and public health service interventions⁹.

Population aging is already a reality in Brazilian society and also a risk factor for the development of chronic diseases due to biological changes, especially in the circulatory system. Studies suggest that by 2025, the population over 60 years old in Brazil will be the sixth largest in the world⁷, and it is expected that approximately 2% of the Brazilian population will develop IC with an incidence of 200 thousand new cases per year^{3,6}. The demographic transition leads to the epidemiological transition, meaning the exchange of the population's disease profile, forcing us to learn how to control elderly people's diseases. This population aging will likely be reflected in the increase in cases of IC and in the increase in costs to the SUS. It was observed that IC presented, during the studied period, an average value per hospitalization of R\$ 1,371.67, generating an average annual economic impact of R\$ 341,137,000. The increase in the cost of hospitalization of patients with IC was from R\$920.78 in 2008 to R\$1,895.66 in 2020, an increase of about 105%. Although there is a tendency to think that greater resources lead to better results, this was not observed when analyzing the data from table 7, which shows an increase in the average length of hospital stay and the mortality rate during the same period.

This cost increase may be related to several causes, including greater severity of patients, justifying the increase in the average length of hospital stay and the number of deaths observed. The multifactorial cause of the increase in the average value includes, in addition to the increase in the average length of hospital stay, the implementation of new therapeutic methods such as the use of stents and cardiac resynchronization, the increase in the performance of cardiac surgeries, and the introduction of new drugs such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) ^{3,10-12}.

In addition, the increase in IPCA, one of the main inflation indicators, during this period (2008-2020) was 103.56%, close to the cost increase observed by the study.

High mortality rates in the age group under 1 year occur mainly due to congenital heart diseases, which are the second leading cause of death in children under 1 year, with an estimated incidence of 1 new case for every 100 births, totaling approximately 28,900 children per year, where up to 80% require cardiac surgery³⁰.

The increase in the in-hospital mortality rate observed in the study may be a result of the paradigm shift in the disease, with the introduction of new therapies such as the use of beta-blockers and spironolactone, drugs with potential for reducing sudden death (a cause of death in up to a third of patients with IC 3,14,15). These drugs increase the survival of severely ill patients. However, as age, pathology, and heart failure progress, these patients tend to die at a later age and in hospital, transferring these deaths, previously extrahospital, to the intra-hospital ones^{10,11}.

It is known that the better the adherence to treatment, the less the need for emergency cardiovascular care¹⁶ and that the need for the use of more than two drugs increases the chances of non-adherence by 2.59%.

CONCLUSIONS

Thus, the study demonstrated that the morbidity profile of heart failure patients registered in the Hospital Information System of the Unified Health System (SUS) is of men, aged 70 to 79, of white ethnicity, from the southeast region, treated under private regime and on an urgent basis. Heart failure is an important public health problem, causing, in addition to a high financial cost to the Unified Health System (SUS), a high morbidity in affected individuals. The study contributes to expanding the analysis of the epidemiological scenario of heart failure patients assisted by SUS, bringing important variables within the context of Brazilian public health, generating evidence and enabling better quality of healthcare provision by health professionals as well as support for the debate of new public policies by authorities and the population aimed at prevention and universal access to health.

REFERENCES

1. Gaudi EN, Oliveira GMM de, Klein CH. Mortality by Heart Failure and Ischemic Heart Disease in Brazil from 1996 to 2011. *Brazilian Archives of Cardiology* [Internet]. 2014 [cited September 16, 2021]; Available from: <http://www.gnresearch.org/doi/10.5935/abc.20140072>
2. DeVore AD, Hammill BG, Sharma PP, Qualls LG, Mentz RJ, Waltman Johnson K, et al. In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. *JAMA* [Internet]. August 15, 2014 [cited September 16, 2021];3(4). Available from: <https://www.ahajournals.org/doi/10.1161/JAHA.114.001088>
3. Bocchi EA, Braga FGM, Ferreira SMA, Issa VS, Ferraz A, Cruz F das D, Guimarães GV, Bacal F, Souza GEC, Moreira LF, Teixeira RA, Azeka E, Ramires F, Simoes MV, Castro RBP de, Salemi VMC. III Brazilian Guideline on Chronic Heart Failure. *Brazilian Archives of Cardiology*. 2009; 93(1): 1-71
4. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editors. *Braunwald's heart disease: a textbook of cardiovascular medicine*. tenth edition. Philadelphia, PA: Elsevier/Saunders; 2015.
5. Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC de, Rassi S, et al. Brazilian Guideline for Chronic and Acute Heart Failure. *ABC* [Internet]. 2018 [cited September 16, 2021]; Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2018001500436
6. Oliveira GMM de, Brant LCC, Polanczyk CA, Biolo A, Nascimento BR, Malta DC, et al. Cardiovascular Statistics – Brazil 2020. *Brazilian Archives of Cardiology*. September 18, 2020;115(3):308–439.
7. Veras RP, Ramos LR, Kalache A. Growth of the elderly population in Brazil: transformations and consequences in society. *Rev Public Health*. June 1987;21(3):225–33.

8. Lebrão ML, Jorge MHP de M, Laurenti R. II - Hospital morbidity by lesions and poisonings. *Rev. public health* [Internet]. 1997 Aug.1 [cited 2021 Sep.16];31(4 suppl.):26-37. Available from: <https://www.revistas.usp.br/rsp/article/view/24290>
9. Brazil, editor. *Epidemiological Surveillance Guide*. 6th ed., [1st reprint]. Brasília, DF: Ministry of Health, Health Surveillance Secretariat, Department of Epidemiological Surveillance; 2006. 815 p. (Series A--Standards and Technical Manuals).
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999;353(9169):2001-7.
11. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med*. 2004;350(21):2140-50.
12. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM Alternative trial. *Lancet*. 2003;362(9386):772-6.
13. Soares AM. Mortality in Congenital Heart Diseases in Brazil - what do we know?. *Brazilian Archives of Cardiology* [online]. 2020;115(6):1174-5. Available from: <https://doi.org/10.36660/abc.20200589>. Epub 18 Jan 2021. ISSN 1678-4170. <https://doi.org/10.36660/abc.20200589>.
14. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J*. 2006;27(22):2725-36.
15. Schaufelberger M, Swedberg K, Köster M, Rosén M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital Discharge Registry 1988 to 2000. *Eur Heart J*. 2004;25(4):300-7.
16. Van der Wal MHL, Jaarsma T. Adherence in heart failure in the elderly: Problem and possible solutions. *Int J Cardiol*. 2008 Apr;125(2):203-8.
17. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005;293(5):572-80.
18. Hawkins NM, Scholes S, Bajekal M, Love H, O'Flaherty M, Raine R, et al. Community care in England: reducing socioeconomic inequalities in heart failure. *Circulation*. 2012;126(9):1050-7.
19. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013 Oct 15;128(16):1810-52.
20. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juillièrè Y, et al. First hospitalization for heart failure in France in 2009: Patient characteristics and 30-day follow-up. *Arch Cardiovasc Dis*. 2013 Nov;106(11):570-85.
21. Poffo MR, Assis AV de, Fracasso M, Londero Filho OM, Alves SM de M, Bald AP, et al. Profile of Patients Hospitalized for Heart Failure in Tertiary Care Hospital. *Int J Cardiovasc Sci* [Internet]. 2017 [cited 2021 Sep 16];30(3):189-197. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472017005028102&lng=en&nrm=iso&tlng=en
22. de Oliveira do Nascimento W, Ribeiro dos Santos AM, Pires Ribeiro I, da Silva Oliveira AD. PROFILE OF ELDERLY HEART FAILURE HOSPITALIZED IN AN EMERGENCY HOSPITAL. *Cogitare Enferm* [Internet]. 2016;21(4). Available from: <https://www.redalyc.org/articulo.oa?id=483653833013>

23. Nogueira PR, Rassi S, Corrêa KS. Epidemiological, clinical and therapeutic profile of heart failure in a tertiary hospital. *Arq Bras Cardiol.* 2010 Sep;95(3):392–8.
24. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. *Eur J Heart Fail.* 2002 Aug;4(4):531–9.
25. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. *Eur J Heart Fail.* 2008 Feb;10(2):140-8.
26. Rassi S, Barretto ACP, Porto CC, Pereira CR, Calaça BW, Rassi DC. Survival and prognostic factors in systolic heart failure with recent onset of symptoms. *Arq Bras Cardiol.* 2005 Apr;84(4):309–13.
27. Barretto ACP, Wajngarten M, Serro-Azul JB, Pierri H, Nussbacher A, Gebara OCE. Drug treatment of heart failure in a tertiary hospital in São Paulo. *Arq Bras Cardiol.* 1997 Dec;69(6):375–9.
28. Albuquerque DC, Souza Neto JD, Bacal F, Rohde LEP, Bernardes-Pereira S, Berwanger O, et al. I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. *Brazilian Archives of Cardiology* [Internet]. 2015 [cited 2021 Sep 16]; Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015000600002
29. Soares LP, Fabbro ALD, Silva AS, Sartorelli DS, Franco LF, Kuhn PC, et al. Cardiovascular Risk in Xavante Indigenous Population. *Brazilian Archives of Cardiology* [Internet]. 2018 [cited 2021 Oct 7]; Available from: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2018000600542
30. Lima-Costa MF, Barreto SM. Types of epidemiological studies: basic concepts and applications in the area of aging. *Epidemiol Serv Saúde* [Internet]. 2003 Dec [cited 2021 Sep 16];12(4). Available from: http://scielo.iec.gov.br/scielo.php?script=sci_arttext&pid=S1679-49742003000400003&lng=pt&nrm=iso&tlng=pt